Expert Insights on First-line Treatment Strategies in SCLC
An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection.
Examining the Promise of Multicancer Early Detection Tests: Existing Concerns
July 5th 2023In this fourth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss existing concerns regarding multicancer early detection tests.
Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy
Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study
Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.
Examining the Promise of Multicancer Early Detection Tests: Need for a Multidisciplinary Clinic
June 28th 2023In this third episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, underscore the need for a multidisciplinary clinic to appropriately interpret multicancer early detection test results.
Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer
Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.
Colorectal Cancer: Evolving Role of ctDNA Testing in Practice
A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.
Examining the Promise of Multicancer Early Detection Tests: Research Efforts Under Way
June 21st 2023In this second episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss some of the challenges faced with randomized control trials and 2 efforts underway that are slated to provide revelatory data on these assays.
ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer
A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.
Strides in GI Cancer Subsets Influence Advances
June 20th 2023Tanios S. Bekaii-Saab, MD, highlights the unmet needs in GI malignancies and discusses how interdisciplinary meetings, such as the 20th Annual Meeting of the International Society of Gastrointestinal Oncology, provide the framework for disseminating information and driving innovative advances.
Examining the Promise of Multicancer Early Detection Tests: Overview and Call for RCTs
June 14th 2023In this first episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, provide an overview on multicancer early detection tests and the need for randomized clinical trials to further explore their use.
Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis
May 19th 2023Morie A. Gertz, MD, discusses the limitations of the current Mayo Stage IV amyloidosis treatment landscape, the rationale for investigating birtamimab in this population, and the importance of raising awareness for the AFFIRM-AL trial.
Ibrutinib-Containing Regimens Remain of Interest Despite Agent’s Withdrawal in MCL and MZL
May 16th 2023Thomas M. Habermann, MD, expands on previous data that supported the initial accelerated approval of ibrutinib in marginal zone lymphoma and mantle cell lymphoma, phase 3 data leading to the agent’s voluntary withdrawal, and investigations of ibrutinib and other BTK inhibitors that could significantly change the treatment landscape in mantle cell lymphoma and marginal zone lymphoma.